Moodle
You are not logged in. (Login)
Skip Check this out...
Show or hide block

Check this out...

Welcome to E-Menai

ambien and alcohol (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U. KPA and APR are currently in the final stages of negotiations with a marketing partner and expect Cambia to launch in 4th quarter 2009. Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act").

.


NewsA Level

Cambia, formulated with KPA's patented Dynamic Buffering Technology (DBT), was specifically developed to address widespread unmet needs among patients by offering fast and effective relief of migraine pain. PALATINE, Ill. About King Pharmaceuticals, Inc. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company's focus in specialty-driven markets, particularly neuroscience and hospital. disclaim any intent or obligation to update these forward-looking statements, and claim the protection of the Safe Harbor for forward-looking statements contained in the Act..